<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>4</volume><submitter>Mansson M</submitter><pubmed_abstract>Lipoprotein (a) [Lp(a)] is a low density lipoprotein (LDL) with one apolipoprotein (a) molecule bound to the apolipoprotein B-100 of LDL. Lp(a) is an independent risk factor for cardiovascular disease (CVD). However, the relationship of Lp(a) to diabetes and metabolic syndrome, both known for increased CVD risk, is controversial. In a population based study on type two diabetes mellitus (T2DM) development in women, Lp(a) plasma levels showed the well known skewed distribution without any relation to diabetes or impaired glucose tolerance. A modified clot lysis assay on a subset of 274 subjects showed significantly increased clot lysis times in T2DM subjects, despite inhibition of PAI-1 and TAFI. Lp(a) plasma levels significantly increased the maximal peak height of the clot lysis curve, in</pubmed_abstract><journal>Scientific reports</journal><pagination>5318</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4060502</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo.</pubmed_title><pmcid>PMC4060502</pmcid><pubmed_authors>Schmidt C</pubmed_authors><pubmed_authors>Bergstrom G</pubmed_authors><pubmed_authors>Legnehed A</pubmed_authors><pubmed_authors>Knecht W</pubmed_authors><pubmed_authors>Amrot-Fors L</pubmed_authors><pubmed_authors>Gustafsson D</pubmed_authors><pubmed_authors>Mansson M</pubmed_authors><pubmed_authors>Kalies I</pubmed_authors><pubmed_authors>Hulten LM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo.</name><description>Lipoprotein (a) [Lp(a)] is a low density lipoprotein (LDL) with one apolipoprotein (a) molecule bound to the apolipoprotein B-100 of LDL. Lp(a) is an independent risk factor for cardiovascular disease (CVD). However, the relationship of Lp(a) to diabetes and metabolic syndrome, both known for increased CVD risk, is controversial. In a population based study on type two diabetes mellitus (T2DM) development in women, Lp(a) plasma levels showed the well known skewed distribution without any relation to diabetes or impaired glucose tolerance. A modified clot lysis assay on a subset of 274 subjects showed significantly increased clot lysis times in T2DM subjects, despite inhibition of PAI-1 and TAFI. Lp(a) plasma levels significantly increased the maximal peak height of the clot lysis curve, in</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 Jun</publication><modification>2025-04-21T16:58:26.87Z</modification><creation>2019-03-27T01:30:20Z</creation></dates><accession>S-EPMC4060502</accession><cross_references><pubmed>24937703</pubmed><doi>10.1038/srep05318</doi></cross_references></HashMap>